Glioblastoma (GBM) cells exhibit aberrant proliferative abilities and resistance to conventional therapies. However, the mechanisms underlying these malignant phenotypes are poorly understood. In this study, we identified ubiquitin-conjugating enzyme E2D1 (UBE2D1) as a crucial stimulator of GBM development. It is highly expressed in GBM and closely associated with poor prognosis in patients with GBM. UBE2D1 knockdown inhibits GBM cell growth and leads to G1 cell cycle arrest. Mechanistically, UBCH5A binds to p21 at the protein level and induces the ubiquitination and degradation of p21. This negative regulation is mediated by STUB1. Our findings are the first to identify UBE2D1 as a key driver of GBM growth and provide a potential target for improving prognosis and therapy.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1002/mc.23786 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
ADAR1 Promotes the Progression and Temozolomide Resistance of Glioma Through p62-Mediated Selective Autophagy.
CNS Neurosci Ther
January 2025
Department of Neurosurgery, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China.
Background: Resistance to temozolomide (TMZ) remains is an important cause of treatment failure in patients with glioblastoma multiforme (GBM). ADAR1, as a member of the ADAR family, plays an important role in cancer progression and chemotherapy resistance. However, the mechanism by which ADAR1 regulates GBM progression and TMZ resistance is still unclear.
View Article and Find Full Text PDFV-ATPase in glioma stem cells: a novel metabolic vulnerability.
J Exp Clin Cancer Res
January 2025
Department of Pathophysiology and Transplantation, University of Milan, Milan, Italy.
Background: Glioblastoma (GBM) is a lethal brain tumor characterized by the glioma stem cell (GSC) niche. The V-ATPase proton pump has been described as a crucial factor in sustaining GSC viability and tumorigenicity. Here we studied how patients-derived GSCs rely on V-ATPase activity to sustain mitochondrial bioenergetics and cell growth.
View Article and Find Full Text PDFMitigating bias in AI mortality predictions for minority populations: a transfer learning approach.
BMC Med Inform Decis Mak
January 2025
Department of Clinical Pharmacy and Translational Science, The University of Tennessee Health Science Center, Memphis, TN, USA.
Background: The COVID-19 pandemic has highlighted the crucial role of artificial intelligence (AI) in predicting mortality and guiding healthcare decisions. However, AI models may perpetuate or exacerbate existing health disparities due to demographic biases, particularly affecting racial and ethnic minorities. The objective of this study is to investigate the demographic biases in AI models predicting COVID-19 mortality and to assess the effectiveness of transfer learning in improving model fairness across diverse demographic groups.
View Article and Find Full Text PDFPeptide-drug conjugates repolarize glioblastoma-associated macrophages to resensitize chemo-immunotherapy of glioblastoma.
Sci Adv
January 2025
School of Life Science, Beijing Institute of Technology, Beijing 100081, China.
The prevalent tumor-supporting glioblastoma-associated macrophages (GAMs) promote glioblastoma multiforme (GBM) progression and resistance to multiple therapies. Repolarizing GAMs from tumor-supporting to tumor-inhibiting phenotype may troubleshoot. However, sufficient accumulation of drugs at the GBM site is restricted by blood-brain barrier (BBB).
View Article and Find Full Text PDFBreaking boundaries: A rare case of glioblastoma with uncommon extraneural metastases: A case report and literature review.
Brain Spine
October 2024
Department of Clinical Medicine, University of Bergen Faculty of Medicine and Dentistry, Bergen, Norway.
Introduction: Extraneural metastases (ENM) from glioblastoma (GBM) remain extremely rare with only a scarce number of cases described in the literature. The lack of cases leads to no consensus on the optimal treatment and follow-up of these patients.
Research Question: Do patient or tumor characteristics describe risk factors for ENM in GBM patients, and is it possible to identify mechanisms of action?
Material And Methods: This study presents a 55-year-old man with diagnosed GBM who was referred to a CT due to reduced general condition and mild back pain which revealed extensive systemic metastases.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!